

Andrea Conti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9502464/publications.pdf>

Version: 2024-02-01

104
papers

3,451
citations

201674

27
h-index

149698

56
g-index

105
all docs

105
docs citations

105
times ranked

3921
citing authors

#	ARTICLE	IF	CITATIONS
1	Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. <i>Nature Medicine</i> , 2006, 12, 1397-1402.	30.7	593
2	Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. <i>British Journal of Dermatology</i> , 2007, 157, 68-73.	1.5	543
3	Diet and physical exercise in psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2014, 170, 634-642.	1.5	146
4	Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 774-790.	2.4	140
5	The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. <i>British Journal of Dermatology</i> , 2020, 183, 373-374.	1.5	104
6	Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF- β 2 signalling in modifying disease severity. <i>Human Molecular Genetics</i> , 2014, 23, 3907-3922.	2.9	88
7	Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1196-1201.	2.4	85
8	Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e30-41.	2.4	75
9	Efficacy and Safety of Systemic Treatments for Psoriasis in Elderly Patients. <i>Acta Dermato-Venereologica</i> , 2014, 94, 293-297.	1.3	71
10	Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. <i>British Journal of Dermatology</i> , 2013, 168, 1124-1127.	1.5	67
11	The clinical spectrum of COVID-19-associated cutaneous manifestations: An Italian multicenter study of 200 adult patients. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1356-1363.	1.2	61
12	Capacitance, transepidermal water loss and causal level of sebum in healthy subjects in relation to site, sex and age. <i>International Journal of Cosmetic Science</i> , 1995, 17, 77-85.	2.6	60
13	Immunogenicity of anti-TNF \pm therapy in psoriasis: a clinical issue?. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1673-1682.	3.1	56
14	Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 257-262.e3.	1.2	54
15	Pruritus characteristics in a large Italian cohort of psoriatic patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1316-1324.	2.4	46
16	Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: Northern Italy experience. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 558-560.e1.	2.9	44
17	Sensitization to reactive textile dyes in patients with contact dermatitis. <i>Contact Dermatitis</i> , 1996, 34, 172-175.	1.4	43
18	Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e360-e361.	2.4	41

#	ARTICLE	IF	CITATIONS
19	Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 271-277.	3.1	40
20	Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 273-275.	1.2	39
21	Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry. <i>British Journal of Dermatology</i> , 2015, 172, 1613-1620.	1.5	36
22	No Alteration of Biophysical Parameters in the Skin of Subjects with Respiratory Atopy. <i>Dermatology</i> , 1996, 192, 317-320.	2.1	35
23	Annular Lichenoid Dermatitis of Youth and Beyond: A Series of 6 Cases. <i>American Journal of Dermatopathology</i> , 2009, 31, 263-267.	0.6	34
24	Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 441-447.	6.7	33
25	Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 863-869.	2.4	31
26	Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e770-e772.	2.4	31
27	Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. <i>British Journal of Dermatology</i> , 2019, 180, 1547-1548.	1.5	30
28	Detection and management of latent tuberculosis infections before biologic therapy for psoriasis. <i>Journal of Dermatological Treatment</i> , 2013, 24, 305-311.	2.2	28
29	COVID-19 and dermatology: a comprehensive guide for dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1388-1394.	2.4	28
30	Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1853-1859.	2.4	27
31	Contact sensitization to preservatives in children. <i>Contact Dermatitis</i> , 1997, 37, 35-36.	1.4	26
32	Psodisk, a new visual method for assessing the burden of psoriasis on patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1163-1166.	2.4	26
33	Psoriasis plaque test with confocal microscopy: evaluation of different microscopic response pathways in NSAID and steroid treated lesions. <i>Skin Research and Technology</i> , 2013, 19, 417-423.	1.6	26
34	Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 157, 1-78.	0.2	25
35	Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 476-483.	2.2	23
36	Cutaneous metastases as the first manifestation of pleural malignant mesothelioma. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 363-365.	1.2	22

#	ARTICLE	IF	CITATIONS
37	The somatic affairs of <i>BRAF</i> : tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations. <i>Journal of Clinical Pathology</i> , 2013, 66, 441-445.	2.0	21
38	Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study. <i>Acta Dermato-Venereologica</i> , 2016, 96, 251-252.	1.3	21
39	Reflectance confocal microscopy for plaque psoriasis therapeutic follow-up during an anti-TNF monoclonal antibody: an observational multicenter study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2363-2368.	2.4	20
40	Anti-drug antibody detection with label-free electrolyte-gated organic field-effect transistors. <i>Chemical Communications</i> , 2021, 57, 367-370.	4.1	20
41	Management of Patients with Psoriasis Treated with Biological Drugs Needing a Surgical Treatment. <i>Drug Development Research</i> , 2014, 75, S24-S26.	2.9	19
42	Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. <i>British Journal of Dermatology</i> , 2017, 177, e325-e326.	1.5	19
43	Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis. <i>PLoS ONE</i> , 2020, 15, e0237267.	2.5	19
44	TOTAL HIP DISARTICULATION PROSTHESIS WITH SUCTION SOCKET. <i>American Journal of Physical Medicine and Rehabilitation</i> , 1999, 78, 160-162.	1.4	19
45	TNF inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 591-598.	3.0	18
46	Seminal Cell Free DNA Concentration Levels Discriminate Between Prostate Cancer and Benign Prostatic Hyperplasia. <i>Anticancer Research</i> , 2018, 38, 5121-5125.	1.1	17
47	Psoriasis and pregnancy outcomes in biological therapies: a real-life, multi-centre experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e374-e377.	2.4	17
48	Etanercept biosimilar <i>SB</i> 4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. <i>British Journal of Dermatology</i> , 2019, 180, 409-410.	1.5	17
49	Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2020, 183, 397-398.	1.5	17
50	Ixekizumab in hidradenitis suppurativa in a psoriatic patient. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2021, 155, 788-789.	0.8	16
51	Dimethyl fumarate treatment for psoriasis in a real-life setting: A multicentric retrospective study. <i>Dermatologic Therapy</i> , 2021, 34, e15066.	1.7	16
52	Sensitization to white petrolatum used as a vehicle for patch testing. <i>Contact Dermatitis</i> , 1995, 33, 201-202.	1.4	15
53	Consensus on the management of patients with psoriatic arthritis in a dermatology setting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 515-528.	2.4	15
54	No Increased Skin Reactivity in Subjects with Allergic Rhinitis During the Active Phase of the Disease: Clinical Report. <i>Acta Dermato-Venereologica</i> , 2000, 80, 192-195.	1.3	14

#	ARTICLE	IF	CITATIONS
55	Secukinumab in multi-failure psoriatic patients: the last hope?. <i>Journal of Dermatological Treatment</i> , 2018, 29, 583-585.	2.2	14
56	Non-invasive evaluation of Secukinumab efficacy in severe plaque psoriasis with confocal microscopy and optical coherence tomography: A case report. <i>Skin Research and Technology</i> , 2018, 24, 160-162.	1.6	12
57	Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies. <i>Journal of Dermatological Treatment</i> , 2018, 29, 5-8.	2.2	11
58	A real-life experience of psoriatic patients with history of cancer treated with biological drugs. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e453-e455.	2.4	11
59	Chronic kidney disease in psoriasis: a cohort study. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 438-445.	0.8	11
60	Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. <i>Dermatologic Therapy</i> , 2017, 30, e12503.	1.7	10
61	Efficacy of ustekinumab after failure of infliximab <sc>CT</sc>â€P13 in a <sc>HLA</sc>â€W6â€positive patient affected by pityriasis rubra pilaris: monitoring with reflectance confocal microscopy (<sc>RCM</sc>) and optical coherence tomography (<sc>OCT</sc>). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e249-e251.	2.4	10
62	Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1561-1566.	3.1	10
63	Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection. <i>Dermatologic Therapy</i> , 2018, 31, e12601.	1.7	9
64	Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience. <i>Dermatology</i> , 2019, 235, 213-218.	2.1	9
65	Psoriasis awareness among Italian patients: results of a nationwide survey. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2016, 151, 1-8.	0.8	9
66	<sc>PSOCUBE</sc>, a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidence-based algorithm. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1310-1317.	2.4	8
67	Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 305-315.	0.2	8
68	Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the <sc>CANOVA</sc> (<sc>Effectiveness</sc> of biologic <sc>treatments</sc> for plaque) <i>Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50</i>	1.7	8
69	Long-term efficacy of high doses of intravenous immunoglobulins in generalized scleromyxoedema: Case report. <i>Journal of International Medical Research</i> , 2016, 44, 109-112.	1.0	7
70	Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis. <i>BioDrugs</i> , 2021, 35, 469-471.	4.6	7
71	How to improve adherence to treatment in patients with mild-to-moderate psoriasis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2018, 153, 692-697.	0.8	7
72	Quantitative description of echographic images of morphea plaques as assessed by computerized image analysis on 20 MHz B-scan recordings.. <i>Acta Dermato-Venereologica</i> , 1995, 75, 442-445.	1.3	7

#	ARTICLE	IF	CITATIONS
73	Monoclonal Gammopathy of Undetermined Significance in Patients with Psoriasis: Is it Really a Side Effect of Biological Therapy?. Drug Development Research, 2014, 75, S35-7.	2.9	6
74	Speckled variance optical coherence tomography for the assessment of nail involvement in acrodermatitis continua of Hallopeau: A case study. Journal of International Medical Research, 2016, 44, 119-123.	1.0	6
75	Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. Breast Cancer, 2019, 26, 520-523.	2.9	6
76	Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2839-2845.	2.4	6
77	Consensus on the place in therapy of TNF inhibitors in the treatment of patients with chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e470-e472.	2.4	6
78	Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis. Dermatologic Therapy, 2020, 33, e13943.	1.7	6
79	Switching infliximab in psoriatic patients during COVID-19 pandemics: A real-life retrospective study comparing intra-versus interclass switching strategies. Dermatologic Therapy, 2021, 34, e15088.	1.7	6
80	A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study. BMC Health Services Research, 2021, 21, 924.	2.2	6
81	In vivo assessment of n-alkyl-sulfate-induced skin irritation by means of non-invasive methods. Skin Research and Technology, 1998, 4, 192-195.	1.6	5
82	Ineffectiveness of infliximab CT-P13 for the treatment of scleromyxedema: A case report. Dermatologic Therapy, 2018, 31, e12583.	1.7	5
83	Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study. Acta Dermato-Venereologica, 2021, 101, adv00576.	1.3	5
84	Validation and Field Performance of the Italian Version of the Psoriatic Arthritis Screening and Evaluation (PASE) Questionnaire. Acta Dermato-Venereologica, 2014, 96, 96-101.	1.3	4
85	Seminal cell-free DNA molecular profile as a novel diagnostic and prognostic prostate cancer biomarkers. Medical Hypotheses, 2018, 114, 69.	1.5	4
86	Use of apremilast in the psoriasis treatment: a real-life multicentre Italian experience. Italian Journal of Dermatology and Venereology, 2021, . .	0.2	4
87	Efficacy of etanercept for the treatment of psoriasis: an overview of the Italian clinical experience from the real-life setting and independent studies. Immunopharmacology and Immunotoxicology, 2012, 34, 901-906.	2.4	3
88	Skeletal and cranio-facial signs in Gorlin syndrome from ancient Egypt to the modern age: sphenoid asymmetry in a patient with a novel PTCH1 mutation. Future Oncology, 2014, 10, 917-925.	2.4	3
89	Use of ustekinumab in five psoriatic patients with hepatitis B virus infection. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 376-377.	0.8	3
90	Investigating psoriasis awareness among patients in Italy: validation of a questionnaire. European Review for Medical and Pharmacological Sciences, 2014, 18, 3435-52.	0.7	3

#	ARTICLE	IF	CITATIONS
91	Moderate to severe psoriasis: a single-center analysis of gender prevalence. Italian Journal of Dermatology and Venereology, 2021, 156, 226-230.	0.2	3
92	Clinical features and in vivo reflectance confocal microscopy of an atypical presentation of Herpesvirusâ€”2 and Cytomegalovirus coâ€”infection of the intergluteal sulcus. Skin Research and Technology, 2017, 23, 619-620.	1.6	2
93	Evaluation of generalized pustular psoriasis by reflectance confocal microscopy. Skin Research and Technology, 2019, 25, 402-403.	1.6	2
94	Phototherapy: The patients' point of view. Photodermatology Photoimmunology and Photomedicine, 2021, 37, 175-179.	1.5	2
95	Does psoriasis influence female sexual dysfunction? A multicentric Italian case-control study. Italian Journal of Dermatology and Venereology, 2022, 157, .	0.2	2
96	Outcome following a short period of adalimumab dose escalation as rescue therapy in psoriatic patients. European Journal of Dermatology, 2020, 30, 159-164.	0.6	2
97	Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics. European Journal of Dermatology, 2021, 31, 493-498.	0.6	2
98	Efficacy and safety of guselkumab in two psoriatic patients with hepatitis B and C virus infection. Dermatologic Therapy, 2022, 35, e15281.	1.7	2
99	Psoriasis improvement after gastric bandage in a patient partial responder to infliximab. Dermatologic Therapy, 2018, 31, e12584.	1.7	1
100	Biological therapy in psoriatic patients wishing fatherhood: a multiâ€”centre italian experience in real life. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e468-e470.	2.4	1
101	P137 Erosive pustular dermatosis of the scalp: A case report. Journal of the European Academy of Dermatology and Venereology, 1997, 9, S185.	2.4	0
102	725. Correction of Laminin-5-Deficient Junctional Epidermolysis Bullosa by Transplantation of Genetically Modified Epidermal Stem Cells. A Phase-I Clinical Trial. Molecular Therapy, 2006, 13, S280.	8.2	0
103	Section 1: Psoriasis. Clinical Drug Investigation, 2013, 33, 63-93.	2.2	0
104	Comments on â€”Diet and psoriasis, part I: Impact of weight loss interventionsâ€”. Journal of the American Academy of Dermatology, 2014, 71, 829.	1.2	0